Smooth muscle cell (SMC) proliferation is a poorly understood process that plays a critical role in several pathological states, including atherosclerosis and hypertension. Recent work suggests that the oncogene c-myb and myosin, a ubiquitous cytoskeletal protein, may be directly involved in this process. We have used antisense nonmuscle myosin heavy chain (NMMHC) or c-myb phosphorothiolate oligonucleotides to inhibit proliferation of SMCs in vitro. The suppression of growth is accompanied by reductions in the concentrations of NMMHC and c-myb mRNAs as well as decreases in the levels of the corresponding proteins. The specificity of the antiproliferative effect is underscored by the absence of any detectable growth inhibition with sense NMMHC or c-myb phosphorothiolate oligonucleotides, an antisense c-myb mismatch phosphorothiolate oligonucleotide, or an antisense thrombomodulin phosphorothiolate oligonucleotide. Furthermore, the treatment of SMCs with antisense phosphorothiolate oligonucleotides for as little as 2 hours causes maximal inhibition of cell growth over the next 72 hours. Under these conditions, SMCs attain normal rates of growth over the following 48 hours, which shows that proliferation is suppressed in a reversible fashion by antisense phosphorothiolate oligonucleotides. These experiments indicate that both c-myb and nonmuscle myosin play critical roles in SMC proliferation and that reductions of either mRNA by antisense phosphorothiolate oligonucleotides arrest the process. (Circulation Research 1992;70:835-843) 
Growth Assay
Both cell lines as well as early passage primary aortic SMCs were seeded at a density of 25,000 cells per well in cluster six-well plates (Costar, Cambridge, Mass.) in 10% FBS-DMEM (20% FBS-DMEM for BC3H1 cells). The following day, the cells were washed twice with phosphate-buffered saline (PBS), and the medium was replaced with 0.5% FBS-DMEM (growth arrest medium). The cells were kept in growth arrest medium for 96 hours. The medium was then changed to 10% or 20% FBS-DMEM, and synthetic oligonucleotides were added. The cells were permitted to grow for 72 hours (unless otherwise specified) and then trypsinized and counted on a Coulter counter. Alternatively, the two cell lines as well as second passage primary aortic SMCs were allowed to proliferate in 10% or 20% FBS-DMEM, oligonucleotides were added, and cell counts were obtained after 5-8 days as described above. Each experiment was carried out in triplicate and repeated at least two additional times. Data are expressed as mean+SD.
RNA Analysis
Total cellular RNA was prepared using the method of Chomczynski and Sacchi36 and quantified by spectrophotometry. Equal amounts of RNA were applied to nitrocellulose for dot blot analysis or subjected to electrophoresis on a denaturing agarose-formaldehyde gel and then transferred to nitrocellulose using a standard protocol.37 Mouse c-myb, human NMMHC, large T antigen, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and TM probes were labeled by random priming (average specific activity, 108 counts per 100 ng) using a Boehringer-Mannheim random primer kit (Mannheim, FRG). Hybridization was carried out in the presence of 10% dextran sulfate and 40% formamide for 16 hours at 42°C. The Northern blots and RNA dot blots were then washed in standard saline citrate (SSC) solution with final washes performed at 50°C and 0.5 x SSC for c-myb, 55°C and 0.2x SSC for NMMHC, 55°C and 0.2x SSC for large T antigen, 50°C and 0.2x SSC for GAPDH, and 50°C and 0.2x SSC for TM. The Northern blots were subjected to autoradiography. The RNA dot blots from SV40LT-SMCs were quantified by normalizing c-myb or GAPDH message counts to large T antigen We next established the minimal time required for exposure of SV40LT-SMCs to antisense NMMHC or c-myb phosphorothiolate oligonucleotides to achieve maximal growth inhibition. In the studies cited above, cells were continuously exposed to oligonucleotides from the time of shift from growth arrest by addition of 10% FBS-DMEM to the measurement of antiproliferative effect by cell count at 72 hours. In the experiments cited below, SV40LT-SMCs were treated with antisense oligonucleotides for stated periods after the shift from growth arrest, washed twice with PBS, placed in fresh oligonucleotide-free 10% FBS-DMEM, and assessed for growth inhibitory effect by cell count at 72 hours ( Figure 3A) . The We also ascertained whether the growth inhibitory effects of antisense phosphorothiolate oligonucleotides are readily reversible. To this end, SV40LT-SMCs were exposed for 4 hours after release from growth arrest to 25 ,uM antisense or sense NMMHC, or c-myb oligonucleotides. The cells were subsequently washed twice with PBS and placed in fresh oligonucleotide-free 10% FBS-DMEM media, and cell counts were determined at day 3 and day 5. The data revealed that proliferation of SV40LT-SMCs treated with antisense NMMHC or c-myb, compared with the corresponding sense oligonucleotides, demonstrates a significant initial suppression of growth at day 3 of about 65% and 50%, respectively. However, the doubling times, between day 3 and day 5 of the SV40LT-SMCs treated with antisense NMMHC or c-myb, compared with the corresponding sense oligonucleotides, were identical at 22 hours.
It is of interest to note that treatment of SV40LT-SMCs with 25 ,tM unmodified antisense NMMHC or c-myb phosphoro-oligonucleotides for 16 hours, after release from growth arrest, produced no discernible antiproliferative effect at 72 hours. In contrast, the continuous exposure for 40 hours to the two oligonucleotides, at identical levels, resulted in the same growth inhibitory effect observed with the phosphorothiolate derivatives ( Figure 3B ). The In similar fashion, Northern blot analyses showed that serum stimulation of SMCs induces a dramatic increase in NMMHC mRNA compared with the preexisting low levels of specific message present in growtharrested cells ( Figure 4B , upper patterns; compare lanes 1 and 2). The exposure of SMCs to 25 ,uM antisense compared with sense NMMHC phosphorothiolate oligonucleotides also led to a marked attenuation of specific message ( Figure 4B , upper gels; compare lanes 3 and 4 and lanes 5 and 6). The equivalent sample loadings of RNA are documented by ethidium bromide staining of gels ( Figure 4B, lower patterns) . In a virtually identical manner, we also evaluated the effects of exposing SMCs to 25 ,uM antisense compared with sense phosphorothiolate TM oligonucleotides. The Northern analyses revealed that TM mRNA is decreased approximately 90% by antisense but not sense oligonucleotides.
The reduction in the concentrations of NMMHC and c-myb mRNAs induced by antisense oligonucleotides should lead to a decrease in the levels of the specific proteins. To show this effect, SV40LT-SMCs were plated at low density (10,000/cm2) on a two-well glass slide (Nunc, Inc., Naperville, Ill.), growth-arrested for 96 hours in 0.5% FBS-DMEM, and then shifted to 10% FBS-DMEM to which were added 25 ,uM antisense or sense NMMHC or c-myb phosphorothiolate oligonucleotides. After 24 hours (c-myb) or 72 hours (NMMHC), SMCs were examined by indirect immunofluorescence microscopy utilizing specific antisera against NMMHC or c-myb. It is readily apparent that the concentrations of NMMHC or c-myb proteins in most cells treated with antisense oligonucleotides are dramatically reduced as compared with those exposed to sense oligonucleotides ( Figure 5) 52 ). This approach has been used by Maciag and colleagues53 to prolong the lifespan of endothelial cells in vitro. The mechanism of action of antisense oligonucleotides is thought to involve binding to an mRNA target sequence, which reduces transport of the message out of the nucleus, and/or marks the message for destruction by RNase H, and/or prevents transcription of the message. 52 The unmodified oligonucleotides can easily be destroyed by serum nucleases, which have stimulated the use of a variety of chemical modifications to prevent degradation. The phosphorothiolate oligonucleotides have been used in this study, which markedly enhance stability of these components without deleteriously effecting the specificity of binding.
We have demonstrated that antisense NMMHC and c-myb phosphorothiolate oligonucleotides significantly inhibit the growth of two different rat SMC lines as well as early passage rat and mouse SMCs. The above treatment is also responsible for a dramatic reduction in the respective mRNAs and proteins as quantitated by Northern analyses or RNA dot blot assays and indirect immunofluorescence with specific antisera for each gene product. The specificity of the antiproliferative effect is underscored by the absence of any detectable growth inhibition with sense NMMHC, or c-myb phosphorothiolate oligonucleotides, or a 2 base pair mismatch antisense c-myb phosphorothiolate oligonucleotide, or an antisense phosphorothiolate TM oligonucleotide. The latter antisense oligonucleotide suppresses the levels of TM mRNA to less than 10% of normal. Thus, SMC growth inhibition by antisense oligonucleotides does not occur because of the formation or degradation of oligonucleotide-mRNA hybrids but requires the targeting of specific mRNAs. The treatment of SMCs with antisense oligonucleotides for as little as 2 hours causes maximal inhibition of cell growth over the next 72 hours. Under these conditions, SMCs attain normal rates of growth over the following 48 hours, which shows that proliferation is suppressed in a reversible fashion by antisense oligonucleotides. On the basis of above data, we believe that antisense oligonucleotides suppress growth of SMCs by selectively reducing the levels of NMMHC and c-myb mRNAs. We also conclude that NMMHC and c-myb must constitute part of the intracellular pathway responsible for SMC proliferation. Furthermore, it is quite likely that heparin and heparan sulfates inhibit SMC growth by reducing expression of c-myb as suggested by us in a prior report."
The exposure of SMCs to unmodified antisense oligonucleotides for 16 hours does not inhibit SMC proliferation at 72 hours, whereas the presence of unmodified antisense oligonucleotides for 40 hours produces suppression of growth comparable to antisense phosphorothiolate oligonucleotides described above. The data are consistent with a 10-to 20-fold slower degradation by SMCs of the antisense phosphorothiolate oligonucleotides as compared to unmodified derivatives. The antiproliferative effects of antisense NMMHC phosphorothiolate oligonucleotides depend entirely on prior growth arrest, whereas the growth inhibitory effects of antisense c-myb phosphorothiolate oligonucleotides are only partially reduced with exponentially growing cells. The ability of antisense c-myb phosphorothiolate oligonucleotides to suppress growth of freely proliferating SMCs is to be expected because the concentrations of target message are at low levels even in the unsynchronized, exponentially growing cells. The lack of any effect of antisense NMMHC phosphorothiolate oligonucleotides on the growth of freely proliferating SMCs is not surprising because of the rapid increase in the levels of target message as cells begin to divide.
The proliferation of SMCs represents the critical event in angioplasty-induced restenosis as well as in the failure of bypass vein grafts.7'8 Despite numerous attempts, with the possible exception of heparin, therapeutic agents are not available to inhibit SMC proliferation initiated by the multitude of potential mitogens outlined above. The optimal compound would be one whose brief application induces a profound but reversible inhibition of a key intracellular step that is required by all mitogens to induce SMC proliferation. This treatment should suppress SMC growth for a sufficient time to allow the normal growth inhibitory mechanisms of the blood vessel wall to be reestablished and might then permit the late proliferation of endothelial cells to cover the damaged area. The antisense NMMHC and c-myb phosphorothiolate oligonucleotides exhibit the above characteristics and are currently being evaluated by our laboratory as therapeutic agents for inhibiting SMC growth in vivo.
